Degron Therapeutics
Mark Ashwell is the Global Head of Chemistry of Degron Therapeutics. He is a world-renowned medicinal chemist, particularly in rational drug design of small molecule inhibitors, with a track record of creating, growing and advancing high value R&D clinical portfolios (>15 INDs). Dr. Ashwell previously served as head of chemistry and executive leadership in Arqule and Nimbus, after 10 years of discovery chemistry in Wyeth, where he led small molecule R&D and technology advancements across multiple target classes and therapeutic areas.
Dr. Ashwell received a BS in chemistry and PhD in Organic Chemistry both from University of Birmingham.
This person is not in any teams
This person is not in any offices
Degron Therapeutics
Dago Bio aims to become the world's leading research and development company for innovative protein degradation drugs-molecular glue-based small molecule new drugs. The Dago team, composed of world-class managers and scientific leaders with international vision and rich industry experience, will focus on the discovery and verification of new, especially undruggable targets of traditional small molecule inhibitors, and the optimization of new compounds. Provide innovative solutions and paths in preclinical and clinical research. It can be used in all therapeutic areas, with the mission of benefiting human health and addressing unmet clinical medical needs.